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Abstract
Chlamydophila pneumoniae infection is ubiquitous. It accounts for 10% of community-acquired pneumonias and 5% of cases of pharyngitis,
bronchitis and sinusitis in both immunocompetent and immunocompromised hosts. It is also involved in exacerbations of chronic bron-
chitis and asthma. Moreover, C. pneumoniae has been reported as a possible cause of atherosclerosis and central nervous system disor-
ders. The current reference standard for serological diagnosis of acute infection is microimmunoﬂuorescence testing, although
molecular detection techniques may well become reference diagnostic tests in the near future. Tetracyclines and erythromycin show
good in vitro activity, and so far have been the most commonly employed drugs in the treatment of C. pneumoniae infection. New mac-
rolides, ketolides and ﬂuoroquinolones are other potentially effective drugs. This review analyses the most recent data concerning the
involvement of C. pneumoniae in human diseases.
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Introduction
In 1989, the previously labelled Chlamydia strain TWAR was
recognized as a third species of the Chlamydia genus and was
named Chlamydia pneumoniae [1]. In 1999, a new taxonomic
classiﬁcation was proposed, renaming the bacterium as
Chlamydophila pneumoniae [2]. The proposal was not univer-
sally accepted, and both names are currently in use by differ-
ent authors. This agent is an obligate intracellular bacterium
that is present in two developmental forms: infective elemen-
tary bodies, and reproductive reticulate bodies. Chlamydiae
multiply within membrane-bound vacuoles in eukaryotic host
cells but are unable to generate ATP and are therefore
dependent on the host cell ATP deposits for all energy
requirements. Moreover, they are incapable of de novo nucle-
otide biosynthesis, and depend on host nucleotide pools.
Epidemiology
C. pneumoniae infection is ubiquitous, with an antibody preva-
lence of 50% by age 20 years and 70–80% at age 60–70 years.
It is a cause of community-acquired pneumonia (CAP), phar-
yngitis, bronchitis, sinusitis, exacerbations of chronic bronchi-
tis and asthma. Moreover, C. pneumoniae has been reported
as a possible cause of atherosclerosis and central nervous
system (CNS) disorders.
Pneumonia
C. pneumoniae is reported to account for a relatively large
number of cases (6–20%) of CAP [3], although data are lar-
gely based on serological determinations alone. The clinical
course may vary from mild, self-limiting illnesses to severe
forms of pneumonia, particularly in elderly patients, and
those with coexisting cardiopulmonary diseases. This agent
participates in co-infection involving other bacterial agents in
approximately 30% of adult cases of CAP [4].
Asthma
An association between asthma and C. pneumoniae infection
was ﬁrst put forward by Hahn et al. in the early 1990s [5]. A
relationship between acute infection with atypical pathogens
and acute asthma exacerbations in children has been sought
in controlled and uncontrolled studies [6]. The vast majority
of studies were concordant in ﬁnding an association between
atypical bacterial infection and asthma exacerbations. Rates
of C. pneumoniae infection identiﬁed in asthma episodes
varied between 4.5% and 25% [6].
Acute atypical infection has been studied in adults with
asthma exacerbations [7]. A recent study revealed that
patients with acute asthma exacerbation and evidence of
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acute infection due to C. pneumoniae exhibited more severe
functional impairment upon admission. In addition, these
patients also showed a slower forced expiratory volume in
1 s (FEV1) rise during follow-up when compared with the
group without acute infection [8].
The relevance of C. pneumoniae in the pathogenesis of
chronic asthma has also been extensively investigated. Accu-
mulating evidence from seroepidemiological studies has
shown that many asthmatics have elevated levels of antibod-
ies to C. pneumoniae [9].
Should the role of C. pneumoniae infection in asthma
patients be proven, C. pneumoniae eradication from the air-
ways would become an important aspect of treatment.
Antibiotics exerting activity against atypical bacteria, e.g.
macrolides, the ketolide telithromycin, tetracyclines and ﬂu-
oroquinolones, would be logical candidates. To date, clinical
trials in children and adults with asthma have mostly involved
macrolides, owing to their favourable tolerability/safety pro-
ﬁle and excellent intracellular accumulation characteristics
[10–13].
A Cochrane review of macrolide usage in treatment of
chronic asthma revealed an overall positive effect on symp-
toms and eosinophilic markers of inﬂammation following
macrolide therapy [14].
A recent multicentre, double-blind, randomized, placebo-
controlled clinical study assessed oral telithromycin as a
supplement to standard-of-care treatment for adults with
acute asthma exacerbations [15]. Ketolide treatment was
associated with statistically signiﬁcant and clinically substan-
tial beneﬁts. In this population, 61% of patients showed evi-
dence of C. pneumoniae and/or Mycoplasma pneumoniae
infection, and the effect of telithromycin on FEV1 was sta-
tistically signiﬁcant in patients with documented infection at
baseline, but not in those without evidence of infection.
However, there were no differences between infection-
positive and infection-negative groups in terms of other
study outcomes, so that the mechanisms causing beneﬁt
remain unclear.
The main limits of the above studies are related to the
size of patient populations and the prevalent use of serology
as the diagnostic test. There is a need for further well-
designed studies to deﬁne both the importance of C. pneumo-
niae involvement in acute and chronic asthma and the useful-
ness of antibiotics in treating this disease.
Chronic obstructive pulmonary disease (COPD)
In patients with COPD, the persistence of microorganisms in
the respiratory tract may facilitate access of different patho-
gens to the lower airways, and long-standing infection might
trigger what is traditionally described as the vicious circle of
chronic bronchitis. Chronic C. pneumoniae infection has been
found to be common in cases of chronic bronchitis, and
could contribute to disease progression through a toxic
effect on bronchial epithelial cells, impairing ciliary function,
and increasing chronic inﬂammation via proinﬂammatory
cytokine production [16,17]. The possibility of chronic colo-
nization with C. pneumoniae in patients with COPD is sup-
ported by serology, electron microscopy and
immunohistochemistry [18,19]. Chronic colonization with
C. pneumoniae is signiﬁcantly associated with more severe
functional impairment, and colonization is associated with a
greater propensity to develop acute exacerbations [20].
Moreover, long-term antibiotic treatment, delivered over a
6-week period, is insufﬁcient to eradicate the organism.
Biological basis for C. pneumoniae involvement in asthma
and chronic airway inﬂammation
Current evidence indicates that C. pneumoniae gene products
(mainly heat shock protein-60), through the activation of
transcription factors (notably nuclear factor kappa-B), are
responsible for the activation of most cellular elements in
bronchial tissue (epithelium, endothelium, monocytes–macro-
phages, smooth muscle cells), resulting in a cascade of cyto-
kine release and adhesion molecule upregulation, which
favours cellular inﬂux into the airways, persistent infection
and airway remodelling. Considering that C. pneumoniae
infection is extremely common in the population, there must
be individual predisposing factors involved in associating this
infection with an asthma phenotype [21]. Fig. 1 summarizes
the interactions between C. pneumoniae and the different cell
types present in airways. In a recent animal model, mice
were inoculated intranasally with C. pneumoniae [22]. C. pneu-
moniae infection caused both sustained airway hyperrespon-
siveness and airway inﬂammation. This has clinical
implications, as changes in airway responsiveness and inﬂam-
mation status induced by this bacterium may worsen and/or
provoke breathlessness in individuals with asthma and
COPD.
Atherosclerosis
The ﬁrst indication that C. pneumoniae has an association
with atherosclerosis and coronary heart disease dates back
to 1986 [23]. This association has been shown by seroepi-
demiology, immunohistochemistry, PCR, electron microscopy
and tissue culture. Animal models of atherosclerosis have
been used to study the role of C. pneumoniae in the initiation
and progression of atherosclerotic disease [24]. The results
of some treatment trials using antibiotics for the prevention
of cardiovascular events in animal models of atherosclerosis
encouraged secondary prevention trials in humans [25,26].
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Small-scale studies indicated that antibiotic treatment may
prevent adverse cardiovascular events. However, large clini-
cal trials failed to demonstrate any effect [27,28]. A compre-
hensive review analysed the epidemiological and
experimental evidence accumulated over the last 20 years
linking C. pneumoniae to atherosclerosis [29]. The authors
conclude that, considering present evidence, C. pneumoniae is
neither sufﬁcient in itself nor necessary to cause atheroscle-
rosis or its clinical consequences in humans. However,
C. pneumoniae is highly likely to be a modiﬁable risk factor
that may be a target of future therapies.
Multiple sclerosis (MS)
C. pneumoniae is detected with higher frequency in the cere-
brospinal ﬂuid of MS patients than in that of neurological
controls. The original ﬁndings of Sriram et al. [30] have been
partially replicated by some, but not all, studies [31–34],
because of genetic heterogeneity, differences in patient selec-
tion, and techniques of DNA extraction or ampliﬁcation.
C. pneumoniae infection seems to characterize a subgroup of
MS patients with an anticipated onset of disease and more
pronounced evidence of CNS inﬂammation/demyelination
[35]. It was also found that C. pneumoniae-infected patients
who were positive according to PCR had more active lesions
than C. pneumoniae-infected patients who were PCR-negative,
suggesting a role for C. pneumoniae in fostering a chronic
inﬂammatory stimulation within the CNS. These ﬁndings led
to the hypothesis that C. pneumoniae might act as a cofactor
that is able to fuel already established inﬂammatory and
demyelinating processes and promote more active disease.
Published data suggest the need for longitudinal observations,
and clinical trials with C. pneumoniae-speciﬁc antibiotics to
clarify the exact role of C. pneumoniae infection in MS
patients [36].
Alzheimer’s disease (AD)
Studies that have used PCR to detect C. pneumoniae in the
brains of AD patients have yielded conﬂicting results [37–39].
A recent study demonstrated that brain tissue samples from
a high proportion of patients with AD are PCR-positive for
C. pneumoniae, but those from age-/sex-matched non-AD
controls are not. Moreover, the organism is viable within the
brains of patients with AD, indicating metabolic activity of
the organism in those tissues [40]. A randomized, placebo-
controlled, multicentre clinical trial has been performed to
determine whether a 3-month course of doxycycline and
rifampin can reduce the decline of cognitive function in
patients with AD [41]. This study showed signiﬁcantly less
cognitive decline at 6 months in the antibiotic group than in
controls. Antibiotic therapy was also associated with less
dysfunctional behaviour at 3 months. There was no clear
relationship between the results and treatment in terms of
eradication of chronic C. pneumoniae infection, suggesting that
the activity of the two drugs may be related to non-antibiotic
effects. None of these observations demonstrates a causal
relationship between CNS infection with C. pneumoniae and
the neuropathogenesis characteristic of AD, but they do
open the way to further investigations.
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FIG. 1. Chlamydophila pneumoniae interaction with different human cell types. BFG, basic ﬁbroblast growth factor; IL, interleukin; MCP, monocyte
chemotactic protein; MHC, major histocompatibility complex; MMP, matrix metalloproteinase; NFjB, nuclear factor kappa-B; PAI-1, plasminogen
activator inhibitor-1; PDGF, platelet-derived growth factor; TEM, transendothelial migration; TF, tissue factor; TNFa, tumour necrosis factor-a.
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Diagnostic Methods
Reliable diagnosis of infection due to C. pneumoniae and inves-
tigation of its role in chronic diseases remain difﬁcult because
of the paucity of well-standardized and commercially available
diagnostic tests that are accurate and reliable (Table 1) [42].
Laboratory methods for the diagnosis of C. pneumoniae infec-
tion include culture, antigen detection, serology and PCR.
Different cell lines have been evaluated for culturing C. pneu-
moniae, and HL and Hep-2 have been found to yield the best
results. So far, successful culture of C. pneumoniae has been
obtained in a limited number of laboratories. The main prob-
lems encountered are easy inactivation during transport, and
low yield, often requiring repeated blind passages.
The sensitivity of antigen detection using direct ﬂuores-
cent antibodies on respiratory specimen smears is esti-
mated to be 20–60% as compared to that of culture; the
speciﬁcity should approach 95%, but this is highly operator-
dependent. This technique is mostly employed for culture
conﬁrmation.
The development of PCR technology has brought major
advantages to the diagnosis of C. pneumoniae infection. It has
been successfully employed with respiratory specimens, lung
and vascular biopsy specimens, and blood. Several studies
have found PCR to be a more sensitive technique than cul-
ture [42]. Nested PCR assays involve signiﬁcant problems
with contamination, which may result in the overestimation
of disease attributed to C. pneumoniae. Real-time assays are
reported to have distinct advantages over conventional
assays [43]. A multiplex PCR has been developed that allows
simultaneous identiﬁcation of C. pneumoniae, Legionella pneu-
mophila and M. pneumoniae in respiratory specimens [44].
The overall diagnostic utility of PCR techniques is currently
hampered by the lack of standardization of extraction proce-
dures, primer deﬁnition, etc., and by the limited number of
commercially available tests. Some are now marketed in
Europe, but none has been approved by the US Food and
Drug Administration.
Serology testing for C. pneumoniae currently includes
microimmunoﬂuorescence (MIF) assays, ELISAs and enzyme
immunoassays, each of which exists in a variety of in-house
and commercial versions. MIF is considered by the CDC to
be the only currently acceptable serological test, and is
considered to be the reference standard for serodiagnosis,
despite signiﬁcant limitations [45].
On the basis of available techniques, the most convincing
evidence of acute infection is obtained when IgM antibodies
or a four-fold rise in IgG antibodies can be shown. However,
the need for paired sera to show a four-fold rise in antibody
titres is a limitation of the MIF technique.
In primary infections, IgM antibodies appear 2–3 weeks
after infection and IgG antibodies appear 6–8 weeks after
infection, whereas in cases of re-infection, IgM antibodies
may be absent, or of low titre if present, and IgG antibodies
appear earlier, within 1–2 weeks after infection.
Recently, a new method for rapid diagnosis of
C. pneumoniae pneumonia has been published [46]. It is
an immunochromatographic test for the detection of
C. pneumoniae-speciﬁc IgM antibodies. The results obtained
with serum samples from 140 patients (41 with C. pneumoniae
pneumonia) using this test were compared with those
obtained using two other serological tests (MIF and enzyme
immunoassay). The reported sensitivity and speciﬁcity of the
test were 100% and 92.9%, respectively. However, as it
detects only the IgM response, the usefulness of this test
may be limited to primary infection.
Treatment
Considering the distinctive characteristics of Chlamydia infec-
tions, the best therapy should combine high intrinsic drug
activity with high intracellular concentrations. Data
TABLE 1. Summary of clinical
relevance of diagnostic techniques
for the identiﬁcation of Chlamydo-
phila pneumoniae
Technique Comments References
Culture Difﬁcult and time-consuming [42]
Antigen detection Suboptimal sensitivity (20–60%), good speciﬁcity (95%)
Little clinical value
[45]
Serology MIF is still the reference standard for acute infection diagnosis
Paired serum samples are required
[42]
[45]
PCR Variable sensitivity and speciﬁcity
Some commercial kits available
Nested PCR may be prone to contamination
Real-time PCR seems to be the most promising technique
Multiplex PCR allows testing for multiple
pathogens with a single test
May become reference diagnostic test in the near
future but is still under evaluation
[44]
[43]
MIF, microimmunoﬂuorescence.
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concerning the in vitro activity of antibiotics against C. pneumo-
niae are relatively limited, owing to the difﬁculty in isolating
the agent and in performing susceptibility tests (Table 2).
Tetracyclines and erythromycin show good in vitro activity
and, so far, have been the most commonly employed drugs
in the treatment of C. pneumoniae infection. The most active
macrolide seems to be clarithromycin [47]. Ketolides have
shown good activity against a broad range of respiratory
pathogens, including Mycoplasma and Chlamydia [48].
Fluoroquinolones show good activity. Levoﬂoxacin is more
active than oﬂoxacin and ciproﬂoxacin. The MIC of moxi-
ﬂoxacin for three strains of C. pneumoniae was 0.6 mg/L, and
the minimal chlamidiacidal concentration values ranged from
0.06 to 0.125 mg/L [49].
The b-lactam target is the bacterial cell wall, a structure
absent in chlamydiae. However, penicillin and ampicillin,
although showing no effect on Chlamydia viability, can inhibit
infectivity [50]. Rifampicin seems to have high activity against
C. pneumoniae, showing MIC and minimal chlamidiacidal con-
centration values ranging from 0.005 to 0.01 mg/L.
A newly described antibiotic, rifalazil (a benzoxazinorifa-
mycin), inhibits bacterial DNA-dependent RNA polymerase
[51]. MIC values of benzoxazinorifamycins for chlamydiae are
in the microgram per litre range.
Eradication of C. pneumoniae during ﬁrst infection is difﬁ-
cult, even with prolonged (up to 3–4 weeks) use of macro-
lides. The length of treatment may be associated with the
long life cycle of Chlamydia, and with the possibility of a qui-
escent phase in the replication of the bacterium. However,
data from clinical trials with new macrolides and ﬂuoro-
quinolones show that clinical cure can be obtained with a
shorter course of therapy. Much more complex is the
eradication of chronic infection. Prolonged macrolide treat-
ment of 6 weeks or more has been suggested, but deﬁnitive
proof of its efﬁcacy is lacking. In order to overcome the
problem of the quiescent phase, multiple-injection therapy
or multiple-drug regimens, including macrolides or ketolides
combined with ﬂuoroquinolones, have been employed.
Conclusions
C. pneumoniae is an obligate, intracellular bacterium associ-
ated with a wide variety of acute and chronic diseases.
C. pneumoniae infection is characterized by persistence and
immunopathological damage to host target tissues, including
the lung. A substantial proportion of lower respiratory
tract infections, including pneumonia and exacerbations of
chronic bronchitis, have been associated with this pathogen.
C. pneumoniae is also involved in both acute and chronic
asthma, and some data link this agent to new-onset asthma
in adults. Over the past 20 years, a variety of studies have
investigated a possible link between C. pneumoniae infection
and atherosclerosis, because of its role in all stages of ath-
erosclerosis, from initial inﬂammatory lesions to plaque
rupture.
This pathogen has been associated with CNS diseases
such as MS and AD. Astrocytes, microglia and neurons all
serve as host cells for C. pneumoniae in the brain of AD
patients, and infected cells are found in close proximity to
both neuritic senile plaques and neuroﬁbrillary tangles.
The interpretation of all these ﬁndings is hampered by the
fact that different studies have used not only different diag-
nostic tools or combinations thereof, but also different diag-
nostic criteria for making a diagnosis of acute or chronic
infection. Most importantly, none of the available methods
has been standardized, which has resulted in a wide variation
of interlaboratory test performance, even when the same
test and the same criteria have been used [42]. The results
of these studies prompted several treatment trials, ranging
from asthma to atherosclerosis and CNS diseases, none of
which gave deﬁnitive results. There is a clear need for fur-
ther well-designed studies to determine both the importance
of C. pneumoniae involvement in human diseases and the use-
fulness of antibiotic treatment.
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TABLE 2. In vitro susceptibility of Chlamydophila pneumoniae
(data taken from [47–49,51])
Drug MIC (mg/L) MCC (mg/L)
Tetracycline 0.05–1 0.05–4
Doxycycline 0.01–0.5 0.12–2
Minocycline 0.016–0.06 0.06–0.125
Erythromycin 0.01–0.5 0.01–0.25
Clarithromycin 0.004–0.25 0.004–0.25
14-OH-clarithromycin 0.03 0.25
Azithromycin 0.01–2 0.06–0.25
Roxythromicin 0.05–2 0.06–2
Telithromycin 0.01–2 0.03–2
Ketolide RU 64004 0.01–0.5 0.01–1
Ciproﬂoxacin 0.25–4 2–8
Oﬂoxacin 0.25–2 0.5–2
Levoﬂoxacin 0.125–0.5 0.125–0.5
Lomeﬂoxacin 0.25 –
Fleroxacin 2–8 2–8
Moxiﬂoxacin 0.06 0.125
Gemiﬂoxacin 0.06–0.25 0.06–0.25
Rifalazil 0.00025 0.004
MCC, minimal chlamydiacidal concentration: ranges of values reported in
literature (values are given as range for clinical isolates or for type strains of
C. pneumoniae).
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